Omnicell Inc（OMCL）财务数据OMCLOmnicell Inc

Omnicell Inc (OMCL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Connected devices, software licenses, and other, accounting for 48.0% of total sales, equivalent to $148.66M. Other significant revenue streams include SaaS and Expert Services and Technical services. Understanding this composition is critical for investors evaluating how OMCL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Omnicell Inc maintains a gross margin of 48.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.39%, while the net margin is 7.78%. These profitability ratios, combined with a Return on Equity (ROE) of 3.06%, provide a clear picture of how effectively OMCL converts its operational activities into shareholder value.

In the context of the broader market, OMCL competes directly with industry leaders such as MGRT and EFOR. With a market capitalization of $1.57B, it holds a leading position in the sector. When comparing efficiency, OMCL's gross margin of 48.98% stands against MGRT's 50.67% and EFOR's 26.54%. Such benchmarking helps identify whether Omnicell Inc is trading at a premium or discount relative to its financial performance.

Omnicell's Q2 2026 net income was $24.3 million, or $0.52 per share, a substantial increase from last year's $5.6 million and $0.12 per share, indicating a recovery in profitability. The gross margin improved to 48.98% in Q2 2026, up from 41.51% in Q4 2025, showing better cost management and operational efficiency.